untitled
<OAI-PMH schemaLocation=http://www.openarchives.org/OAI/2.0/ http://www.openarchives.org/OAI/2.0/OAI-PMH.xsd>
<responseDate>2018-01-15T18:33:10Z</responseDate>
<request identifier=oai:HAL:hal-00875148v1 verb=GetRecord metadataPrefix=oai_dc>http://api.archives-ouvertes.fr/oai/hal/</request>
<GetRecord>
<record>
<header>
<identifier>oai:HAL:hal-00875148v1</identifier>
<datestamp>2017-12-21</datestamp>
<setSpec>type:ART</setSpec>
<setSpec>subject:sdv</setSpec>
<setSpec>collection:UNIV-ST-ETIENNE</setSpec>
<setSpec>collection:UNIV-AG</setSpec>
<setSpec>collection:IFR140</setSpec>
<setSpec>collection:IMRB</setSpec>
<setSpec>collection:IRSET</setSpec>
<setSpec>collection:UNIV-RENNES1</setSpec>
<setSpec>collection:APHP</setSpec>
<setSpec>collection:IRSET-HIAEC</setSpec>
<setSpec>collection:BIOSIT</setSpec>
<setSpec>collection:UPEC-UPEM</setSpec>
<setSpec>collection:UR1-UFR-SVE</setSpec>
<setSpec>collection:STATS-UR1</setSpec>
<setSpec>collection:UR1-HAL</setSpec>
<setSpec>collection:EHESP</setSpec>
<setSpec>collection:USPC</setSpec>
<setSpec>collection:UR1-SDV</setSpec>
<setSpec>collection:IRSET-2</setSpec>
<setSpec>collection:UNIV-ANGERS</setSpec>
<setSpec>collection:UNIV-PSUD</setSpec>
</header>
<metadata><dc>
<publisher>HAL CCSD</publisher>
<title lang=en>Long-term immunogenicity of two doses of 2009 A/H1N1v vaccine with and without AS03(A) adjuvant in HIV-1-infected adults.</title>
<creator>Durier, Christine</creator>
<creator>Desaint, Corinne</creator>
<creator>Lucht, Frédéric</creator>
<creator>Girard, Pierre-Marie</creator>
<creator>Lévy, Yves</creator>
<creator>May, Thierry</creator>
<creator>Michelet, Christian</creator>
<creator>Rami, Agathe</creator>
<creator>Roman, François</creator>
<creator>Delfraissy, Jean-François</creator>
<creator>Aboulker, Jean-Pierre</creator>
<creator>Launay, Odile</creator>
<contributor>Essais Therapeutiques et Infection Par Le Vih ; Université Paris-Sud - Paris 11 (UP11) - Institut National de la Santé et de la Recherche Médicale (INSERM)</contributor>
<contributor>CIC - Biotherapie - AP-HP (cochin - Pasteur) ; Institut National de la Santé et de la Recherche Médicale (INSERM)</contributor>
<contributor>Groupe Immunité des Muqueuses et Agents Pathogènes (GIMAP) ; Université Jean Monnet [Saint-Étienne] (UJM)</contributor>
<contributor>Institut Mondor de Recherche Biomédicale (IMRB) ; Université Paris-Est Créteil Val-de-Marne - Paris 12 (UPEC UP12) - Institut National de la Santé et de la Recherche Médicale (INSERM) - IFR10</contributor>
<contributor>Service des maladies infectieuses et tropicales [Nancy-Brabois] ; Hôpital de Brabois [CHRU Nancy] ; Centre Hospitalier Régional Universitaire de Nancy (CHRU Nancy) - Centre Hospitalier Régional Universitaire de Nancy (CHRU Nancy)</contributor>
<contributor>Institut de recherche, santé, environnement et travail [Rennes] (Irset) ; Université d'Angers (UA) - Université des Antilles et de la Guyane (UAG) - Université de Rennes 1 (UR1) - École des Hautes Études en Santé Publique [EHESP] (EHESP) - Institut National de la Santé et de la Recherche Médicale (INSERM) - Structure Fédérative de Recherche en Biologie et Santé de Rennes ( Biosit : Biologie - Santé - Innovation Technologique )</contributor>
<contributor>Service de médecine interne et maladies infectieuses ; Université Paris-Sud - Paris 11 (UP11) - Assistance publique - Hôpitaux de Paris (AP-HP) - Hôpital Bicêtre</contributor>
<contributor>French National Agency for Research on AIDS and Viral Hepatitis (ANRS, Paris, France)</contributor>
<description>International audience</description>
<source>ISSN: 0269-9370</source>
<source>AIDS</source>
<publisher>Lippincott, Williams & Wilkins</publisher>
<identifier>hal-00875148</identifier>
<identifier>https://hal.archives-ouvertes.fr/hal-00875148</identifier>
<source>https://hal.archives-ouvertes.fr/hal-00875148</source>
<source>AIDS, Lippincott, Williams & Wilkins, 2013, 27 (1), pp.87-93. 〈10.1097/QAD.0b013e328359f27a〉</source>
<identifier>DOI : 10.1097/QAD.0b013e328359f27a</identifier>
<relation>info:eu-repo/semantics/altIdentifier/doi/10.1097/QAD.0b013e328359f27a</relation>
<identifier>PUBMED : 23018437</identifier>
<relation>info:eu-repo/semantics/altIdentifier/pmid/23018437</relation>
<language>en</language>
<subject>[SDV.IMM.VAC] Life Sciences [q-bio]/Immunology/Vaccinology</subject>
<type>info:eu-repo/semantics/article</type>
<type>Journal articles</type>
<description lang=en>OBJECTIVE: In immunocompromised patients, alternative schedules more immunogenic than the standard influenza vaccine regimen are necessary to enhance and prolong vaccine efficacy. We previously reported that the AS03A-adjuvanted 2009 A/H1N1v vaccine yielded a higher short-term immune response than the nonadjuvanted one in HIV-1-infected adults. This study reports the long-term persistence of the immune response. DESIGN AND METHODS: In a prospective, multicenter, randomized, patient-blinded trial, two doses of AS03A-adjuvanted H1N1v vaccine containing 3.75 μg haemagglutinin (n = 155; group A) or nonadjuvanted H1N1v vaccine containing 15 μg haemagglutinin (n = 151; group B), were administered 21 days apart. Haemagglutination inhibition and neutralizing antibodies were assessed 6 and 12 months after vaccination. RESULTS: In group A and B, the seroprotection rates were 83.7 and 59.4% at month 6, and 70.4 and 49.3 at month 12, respectively. In a multivariate analysis, persistence of seroprotection 12 months after vaccination was negatively associated with current smoking (odds ratio = 0.6, P = 0.03) and positively related with the AS03A-adjuvanted H1N1v vaccine (odds ratio = 2.7, P = 0.0002). CONCLUSION: In HIV-1-infected adults, two doses of adjuvanted influenza vaccine induce long-term persistence of immune response up to 1 year after vaccination.</description>
<contributor>ANRS 151 study group and the REIVAC network</contributor>
<date>2013-01-02</date>
</dc>
</metadata>
</record>
</GetRecord>
</OAI-PMH>